期刊文献+

3株新城疫病毒体外对人喉癌Hep-2细胞杀伤效应的比较 被引量:2

In Vitro Killing Effects of 3 Newcastle Disease Virus Strains on Human Throat Cancer Hep-2 Cells
原文传递
导出
摘要 目的比较新城疫病毒(NDV)强毒株D817、弱毒株7793和La Sota疫苗株对人喉癌Hep-2细胞的杀伤效应。方法3株病毒经扩增、噬斑纯化后,分别感染Hep-2细胞和喉正常组织细胞,一定时间后,显微镜下观察细胞形态变化,MTT比色法检测病毒对细胞的杀伤效应。结果3株病毒均能在Hep-2细胞中增殖并杀伤细胞,杀伤效应以D817株最高,La Sota株其次,7793株最低,且差异均无统计学意义。杀伤效应与病毒剂量和作用时间呈正相关,显微镜下可见明显的细胞病变。而对喉正常组织细胞的杀伤效应不明显。结论NDV D817株和7793株对喉癌细胞的杀伤效应与La Sota疫苗株相似,而对喉正常组织细胞的杀伤效应不明显,有望成为喉癌生物学治疗新的候选病毒株。 Objective To compare the in vitro killing effects of 3 Newcastle disease virus (NDV) strains on human throat cancer Hep-2 cells. Methods The virulent D817, attenuated 7793 and La Sota strains of NDV were proliferated and purified, then used for infection of Hep-2 cells respectively, using norulal human throat tissue cells as control. The morphological change of Hep-2 cells was observed by microscopy, and the killing effect was determined by MTI' method. Results All the 3 virus strains were prolif- erated in Hep-2 cells and killed the cells, while showed no significantly killing effect on normal throat tissue cells. In the turn of killing effect on Hep-2 cells, the 3 strains were D817, La Sota and 7793. However, no significant differences were observed between killing effects of the 3 strains. The killing effect was positively related to the dosage of virus and time for treatment. Obvious CPE of Hep-2 cells was observed by microscopy. Conclusion The killing effects of D817 and 7793 strains of NDV on Hep-2 cells were equivalent to that of La Sota strain. However, neither of the strain showed significantly killing effect on normal throat tissue cells, indicating that D817 and 7793 strains might be used as novel candidate virus strains for biotherapy of throat cancer.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第1期10-13,共4页 Chinese Journal of Biologicals
基金 广西壮族自治区研究生教育创新计划(2006105981001M03) 广西留学回国科学基金(0342013) 教育部留学回国人员科研启动基金(2004-2007)
关键词 新城疫病毒 喉癌 杀伤效应 Newcastle disease virus Throat cancer Killing effect
  • 相关文献

参考文献12

  • 1Bar-Eli N, Giloh H, Schlesinger M, et al. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol, 1996, 122(7): 409-415.
  • 2Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol, 2006, 80( 15): 7522-7534.
  • 3Csatary LK, Gosztonyi G, Szeberenyi J, et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol, 2004, 67( 1-2): 83-93.
  • 4Pecora AL, Rizvi N, Cohen GI, et al. Phase Ⅰ trial of intravenous administration of PVT01, an oneolytic virus, in patients with advanced solid cancers. J Clin Oncol, 2002, 20(9): 2251-2266.
  • 5管国芳,金春顺,金宁一,张静敏,米志强,李霄,连海,孙丽丽,文连姬,崔葳.新城疫病毒致Hep-2肿瘤细胞死亡方式的研究[J].中国生物制品学杂志,2005,18(6):461-464. 被引量:3
  • 6Csatary LK, Moss RW, Beuth J, et al. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res, 1999, 19( 1B): 635-63$.
  • 7Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol, 2001, 18(5): 945-952.
  • 8Phuangsab A, Eorence RM, Reichard KW, et al. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett, 2001, 172( 1 ): 27-36.
  • 9Schlag P, Manasterki M, Geneth T, et al. Active specific immunotherapy with Newcastle-disease-virus modified autologous tumor cells following resection of liver metastasis in colorectal cancer. First evaluation of clinical response of phose Ⅱ trial. Cancer Immunol lmmunother, 1992, 35 ( 5 ): 325.
  • 10Liebrich WT, Schlag P, Manasterki M, et al. In vitro and clinical characterization of a Newcastle-disease-virus modified autologoas tumor cell vaccine for treatment of colorectal cancer patients. Eur J Cancer, 1991, 27(6): 703.

二级参考文献7

  • 1Csatary LK, Moss RW, Beuth J, et al. Beneficial treatment of patients with advanced cancer using a newcastle disease virus vaccine(MTH-68/H).Anticancer Res, 1999,19:635-638.
  • 2Pecora AL,Rizvi N,Cohen GI,et al. Phase Ⅰ trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol,2002,20:2220-2222.
  • 3Schirrmacher V, Bai L, Umansky V, et al. Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol, 2000, 16: 363-373.
  • 4Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of newcastle disease virus in vivo: local versus systemic effects. Int J Oncol,2001,18:945-952.
  • 5Sinkovics JG, Horvath JC. Newcastle disease virus(NDV): brief history of its oncolytic strains. J Clin Virol,2000,16:1-15.
  • 6Schirrmacher V, Haas C, Bonifer R, et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using newcastle disease virus. Gene Ther, 1999,6: 63 -73.
  • 7Weaver BK, Ando O, Kumar KP, et al. Apoptosis is promoted by the dsRNA-activated factor( DRAF1 ) during viral infection independent of the action of interferon or p53.FASEB J,2001,15:501-515.

共引文献2

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部